scispace - formally typeset
K

Kan Chen

Researcher at Erasmus University Rotterdam

Publications -  18
Citations -  588

Kan Chen is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Cell growth & Gene knockdown. The author has an hindex of 11, co-authored 18 publications receiving 437 citations. Previous affiliations of Kan Chen include Minzu University of China & Zhejiang Sci-Tech University.

Papers
More filters
Journal ArticleDOI

Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus

TL;DR: These findings should be considered when physicians select immunosuppressive therapies for recipients of organ transplants who are infected with HEV, and the combination of MPA and ribavirin had a greater ability to inhibit HEV replication than MPA or ribavirus alone.
Journal ArticleDOI

Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections.

TL;DR: It is found that IFN-independent ISG expression was detectable in immortalized cell lines, primary intestinal and liver organoids, and liver tissues, and it is suggested that the U-ISGF3 complex is both necessary and sufficient for constitutive ISGs expression and antiviral immunity under homeostatic conditions.
Journal ArticleDOI

Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans.

TL;DR: This review will comprehensively describe the current in vitro and mouse models for studying NAFLD/NASH/HCC, and further emphasize their applications and possible future improvement for better understanding the molecular mechanisms involved in the cascade ofNAFLD to HCC progression.
Journal ArticleDOI

LGR5 marks targetable tumor-initiating cells in mouse liver cancer

TL;DR: The enrichment of L GR5 expressing cells, a well-recognized stem cell marker, in mouse liver tumors, and the upregulation of LGR5 expression in human hepatocellular carcinoma are reported, representing a viable therapeutic target for combating liver cancer.